Contemporary Management of Acute Lymphoblastic Leukemia
Key Features
• Comprehensive and up-to-date coverage of the epidemiology, molecular pathogenesis, and cytogenetics of ALL
• Extensive discussion of clinical trial data in childhood and adult ALL
• Chapters devoted to in-depth coverage of key aspects of therapy including use of asparaginase, treatment of central nervous system ALL, and management of long-term sequelae
• Detailed coverage of emerging areas including minimal residual disease monitoring and pharmacogenomics
• Discussion of novel therapies including bispecific T-cell engaging antibody therapy and chimeric antigen receptor expressing T-cell therapy.
• Extensive discussion of clinical trial data in childhood and adult ALL
• Chapters devoted to in-depth coverage of key aspects of therapy including use of asparaginase, treatment of central nervous system ALL, and management of long-term sequelae
• Detailed coverage of emerging areas including minimal residual disease monitoring and pharmacogenomics
• Discussion of novel therapies including bispecific T-cell engaging antibody therapy and chimeric antigen receptor expressing T-cell therapy.
MRP
TBA
Inclusive of all taxes
Key Features
• Comprehensive and up-to-date coverage of the epidemiology, molecular pathogenesis, and cytogenetics of ALL
• Extensive discussion of clinical trial data in childhood and adult ALL
• Chapters devoted to in-depth coverage of key aspects of therapy including use of asparaginase, treatment of central nervous system ALL, and management of long-term sequelae
• Detailed coverage of emerging areas including minimal residual disease monitoring and pharmacogenomics
• Discussion of novel therapies including bispecific T-cell engaging antibody therapy and chimeric antigen receptor expressing T-cell therapy.
• Extensive discussion of clinical trial data in childhood and adult ALL
• Chapters devoted to in-depth coverage of key aspects of therapy including use of asparaginase, treatment of central nervous system ALL, and management of long-term sequelae
• Detailed coverage of emerging areas including minimal residual disease monitoring and pharmacogenomics
• Discussion of novel therapies including bispecific T-cell engaging antibody therapy and chimeric antigen receptor expressing T-cell therapy.
MRP
TBA
Inclusive of all taxes
Description
Acute lymphoblastic leukemia (ALL), the commonest childhood leukemia, is now an eminently curable disease in children, thanks to developments in chemotherapy over the last 6 decades. However, adult ALL still remains a therapeutic challenge, particularly in older patients who are not candidates for intensive chemotherapy or hematopoietic stem cell transplantation (HSCT). Much work, therefore, remains to be done in order to improve outcomes of adult patients as well as patients with relapsed disease. This book is an attempt to compile the latest advances in the understanding of the pathogenesis of ALL as well as various aspects of its treatment.
Product Details
Publisher :
JPB
Edition :
1/e
Binding :
Hard Back
Language :
English
Pages :
350
ISBN-13 :
9789351522416
Item Weight :
740 grams
Dimensions :
6.5 x 9
Printing Format Color :
Four Color
Copyright year :
2014